Assessment of the safety and efficacy of low pathogenic avian influenza (H9N2) virus in inactivated oil emulsion vaccine in laying hens
- PMID: 27051337
- PMCID: PMC4808641
- DOI: 10.4142/jvs.2016.17.1.27
Assessment of the safety and efficacy of low pathogenic avian influenza (H9N2) virus in inactivated oil emulsion vaccine in laying hens
Abstract
In Korea, several outbreaks of low pathogenic AI (H9N2) viral infections leading to decreased egg production and increased mortality have been reported on commercial farms since 1996, resulting in severe economic losses. To control the H9N2 LPAI endemic, the Korea Veterinary Authority has permitted the use of the inactivated H9N2 LPAI vaccine since 2007. In this study, we developed a killed vaccine using a low pathogenic H9N2 AI virus (A/chicken/Korea/ADL0401) and conducted safety and efficacy tests in commercial layer farms while focusing on analysis of factors that cause losses to farms, including egg production rate, egg abnormality, and feed efficiency. The egg production rate of the control group declined dramatically 5 days after the challenge. There were no changes in feed consumption of all three groups before the challenge, but rates of the control declined afterward. Clinical signs in the vaccinated groups were similar, and a slight decline in feed consumption was observed after challenge; however, this returned to normal more rapidly than the control group and commercial layers. Overall, the results of this study indicate that the safety and efficacy of the vaccine are adequate to provide protection against the AI field infection (H9N2) epidemic in Korea.
Keywords: H9N2; avian influenza virus; immunity; vaccine.
Conflict of interest statement
Figures






Similar articles
-
A Dose-Response Study of Inactivated Low Pathogenic Avian Influenza H9N2 Virus in Specific-Pathogen-Free and Commercial Broiler Chickens.Avian Dis. 2016 May;60(1 Suppl):256-61. doi: 10.1637/11143-050815-Reg. Avian Dis. 2016. PMID: 27309065
-
Enhancing immunogenicity and protective efficacy of inactivated avian influenza H9N2vaccine with recombinant chicken IFN-α in chicken.Vet Microbiol. 2019 Jul;234:77-82. doi: 10.1016/j.vetmic.2019.05.015. Epub 2019 May 21. Vet Microbiol. 2019. PMID: 31213275
-
H9N2 avian influenza virus-induced conjunctivitis model for vaccine efficacy testing.Avian Dis. 2013 Mar;57(1):83-7. doi: 10.1637/10240-050712-Reg.1. Avian Dis. 2013. PMID: 23678734 Clinical Trial.
-
Principles for vaccine protection in chickens and domestic waterfowl against avian influenza: emphasis on Asian H5N1 high pathogenicity avian influenza.Ann N Y Acad Sci. 2006 Oct;1081:174-81. doi: 10.1196/annals.1373.021. Ann N Y Acad Sci. 2006. PMID: 17135509 Review.
-
Development and use of fowlpox vectored vaccines for avian influenza.Ann N Y Acad Sci. 2006 Oct;1081:193-201. doi: 10.1196/annals.1373.023. Ann N Y Acad Sci. 2006. PMID: 17135511 Review.
Cited by
-
A G1-lineage H9N2 virus with oviduct tropism causes chronic pathological changes in the infundibulum and a long-lasting drop in egg production.Vet Res. 2018 Aug 29;49(1):83. doi: 10.1186/s13567-018-0575-1. Vet Res. 2018. PMID: 30157967 Free PMC article.
-
A Live Attenuated H9N2 Avian Influenza Vaccine Prevents the Viral Reassortment by Exchanging the HA and NS1 Packaging Signals.Front Microbiol. 2021 Feb 4;11:613437. doi: 10.3389/fmicb.2020.613437. eCollection 2020. Front Microbiol. 2021. PMID: 33613465 Free PMC article.
-
Naringenin as a phytogenic adjuvant systematically enhances the protective efficacy of H9N2 inactivated vaccine through coordinated innate-adaptive immune priming in chickens.Poult Sci. 2025 Aug;104(8):105257. doi: 10.1016/j.psj.2025.105257. Epub 2025 May 2. Poult Sci. 2025. PMID: 40344923 Free PMC article.
-
Dose immunogenicity study of a plant-produced influenza virus-like particle vaccine in layer hens.Heliyon. 2022 Jun 25;8(6):e09804. doi: 10.1016/j.heliyon.2022.e09804. eCollection 2022 Jun. Heliyon. 2022. PMID: 35785234 Free PMC article.
-
Protective Efficacy of H9N2 Avian Influenza Vaccines Inactivated by Ionizing Radiation Methods Administered by the Parenteral or Mucosal Routes.Front Vet Sci. 2022 Jul 11;9:916108. doi: 10.3389/fvets.2022.916108. eCollection 2022. Front Vet Sci. 2022. PMID: 35898545 Free PMC article.
References
-
- Allan WH, Lancaster JE, Tóth B. Newcastle Disease Vaccines: Their Production and Use. Rome: Food and Agriculture Organization of the United Nations; 1978. pp. 54–94.
-
- Banks J, Speidel EC, Harris PA, Alexander DJ. Phylogenetic analysis of influenza A viruses of H9 haemagglutinin subtype. Avian Pathol. 2000;29:353–359. - PubMed
-
- Beard CW, Schnitzlein WM, Tripathy DN. Protection of chickens against highly pathogenic avian influenza virus (H5N2) by recombinant fowlpox viruses. Avian Dis. 1991;35:356–359. - PubMed
-
- Breytenbach JH. Vaccination and biosecurity is the key. Poult World. 2005;159:33.
-
- Capua I, Mutinelli F, Marangon S, Alexander DJ. H7N1 avian influenza in Italy (1999 to 2000) in intensively reared chickens and turkeys. Avian Pathol. 2000;29:537–543. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical